Merck and Ridgeback Biotherapeutics partner announced today that six laboratory studies have shown that their experimental COVID-19 drug molnupiravir works against the highly contagious Omicron variant of the coronavirus.
Data evaluated the antiviral activity of molnupiravir and other antiviral agents against COVID-19 anxiety variants. The efficacy of molnupiravir against Omicron has not yet been tested in human studies, the companies said.
Molnupiravir and a Pfizer pill, also taken orally, were licensed in the United States in December and are considered important tools against Omicron.
Pfizer announced in December that laboratory data showed that its drug, Paxlovid, maintained its effectiveness against Omicron.
Merck announced earlier this month that its pill has a mechanism that can work against Omicron and any other variant.
Molnupiravir is licensed in more than ten countries, including the United States, the United Kingdom, and Japan.
See all the news
Follow Skai.gr on Google News
and be the first to know all the news
_002115.jpg?fit=%2C&ssl=1)
